Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03669718
Recruitment Status : Recruiting
First Posted : September 13, 2018
Last Update Posted : November 8, 2019
Sponsor:
Collaborator:
Regeneron Pharmaceuticals
Information provided by (Responsible Party):
ISA Pharmaceuticals

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : February 2020
Estimated Study Completion Date : February 2022